
Lupin Limited, a global pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Ganirelix Acetate Injection. This approval allows Lupin to market a generic equivalent of Organon USA LLC's reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL Single-Dose Prefilled Syringe. This injection marks Lupin's entry into the peptide-based injectables sector, showcasing the company's dedication to innovative healthcare solutions. Ganirelix Acetate Injection is designed for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Like
Save
Share